Human-induced pluripotent stem cell-derived cardiomyocytes exhibit temporal changes in phenotype

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 6, 2013, Pages

  Ivashchenko, Christine Y ^a   Pipes, Gordon C ^a   Lozinskaya, Irina M ^a   Lin, Zuojun ^a   Xiaoping, Xu ^a   Needle, Saul ^a   Grygielko, Eugene T ^a   Hu, Erding ^a   Toomey, John R ^a   Lepore, John J ^a   Willette, Robert N ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Human iPS derived cardiomyocytes hiPS CM; In vitro differentiation; Maturation

Indexed keywords

ION CHANNEL;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; GENE EXPRESSION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE; MARKER GENE; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

HUMAN IPS-DERIVED CARDIOMYOCYTES/HIPS-CM; IN VITRO DIFFERENTIATION; MATURATION;

ACTION POTENTIALS; CALCIUM SIGNALING; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; ION CHANNELS; MYOCYTES, CARDIAC; PHENOTYPE; PLURIPOTENT STEM CELLS;

EID: 84884364320     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00819.2012     Document Type: Article

References (72)

1. Ameen C, Strehl R, Bjorquist P, Lindahl A, Hyllner J, Sartipy P. Human embryonic stem cells: current technologies and emerging industrial applications. Crit Rev Oncol Hematol 65: 54-80, 2008.
2. Anson BD, Kolaja KL, Kamp TJ. Opportunities for use of human iPS cells in predictive toxicology. Clin Pharmacol Ther 89: 754-758, 2011.
3. Bahadur G, Morrison M. Patenting human pluripotent cells: balancing commercial, academic and ethical interests. Hum Reprod 25: 14-21, 2010.
4. Binah O, Dolnikov K, Sadan O, Shilkrut M, Zeevi-Levin N, Amit M, Danon A, Itskovitz-Eldor J. Functional and developmental properties of human embryonic stem cells-derived cardiomyocytes. J Electrocardiol 40: S192-S196, 2007.
5. Blin G, Neri T, Stefanovic S, Puceat M. Human embryonic and induced pluripotent stem cells in basic and clinical research in cardiology. Curr Stem Cell Res Ther 5: 215-226, 2012.
6. Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res 91: 189-201, 2002.
7. Braam SR, Passier R, Mummery CL. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. Trends Pharmacol Sci 30: 536-545, 2009.
8. Capi O, Gepstein L. Myocardial regeneration strategies using human embryonic stem cell-derived cardiomyocytes. J Control Release 116: 211-218, 2006.
9. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465: 808-812, 2012.
10. Choukroun G, Hajjar R, Kyriakis JM, Bonventre JV, Rosenzweig A, Force T. Role of the stress-activated protein kinases in endothelin-induced cardiomyocyte hypertrophy. J Clin Invest 102: 1311-1320, 1998.
11. de Boer TP, van Rijen HV, Van der Heyden MA, Kok B, Opthof T, Vos MA, Jongsma HJ, de Bakker JM, van Veen TA. Beta-, not alpha-adrenergic stimulation enhances conduction velocity in cultures of neonatal cardiomyocytes. Circ J 71: 973-981, 2007.
12. Dick E, Rajamohan D, Ronksley J, Denning C. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 38: 1037-1045, 2010.
13. Dillmann W. Cardiac hypertrophy and thyroid hormone signaling. Heart Fail Rev 15: 125-132, 2012.
14. Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc Natl Acad Sci USA 91: 1686-1690, 1994.
15. Engelmann GL, Campbell SE, Rakusan K. Immediate postnatal rat heart development modified by abdominal aortic banding: analysis of gene expression. Mol Cell Biochem 163-164: 47-56, 1996.
16. Freund C, Mummery CL. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. J Cell Biochem 107: 592-599, 2009.
17. Gai H, Leung EL, Costantino PD, Aguila JR, Nguyen DM, Fink LM, Ward DC, Ma Y. Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. Cell Biol Int 33: 1184-1193, 2009.
18. Gassanov N, Er F, Endres-Becker J, Wolny M, Schramm C, Hoppe UC. Distinct regulation of cardiac I(f) current via thyroid receptors alpha1 and beta1. Pflügers Arch 458: 1061-1068, 2009.
19. Heidi Au HT, Cui B, Chu ZE, Veres T, Radisic M. Cell culture chips for simultaneous application of topographical and electrical cues enhance phenotype of cardiomyocytes. Lab Chip 9: 564-575, 2009.
20. Hess P, Lansman JB, Nilius B, Tsien RW. Calcium channel types in cardiac myocytes: modulation by dihydropyridines and beta-adrenergic stimulation. J Cardiovasc Pharmacol 8, Suppl 9: S11-S21, 1986.
21. Hudlicka O, Brown MD. Postnatal growth of the heart and its blood vessels. J Vasc Res 33: 266-287, 1996.
22. Kalofoutis C, Mourouzis I, Galanopoulos G, Dimopoulos A, Perimenis P, Spanou D, Cokkinos DV, Singh J, Pantos C. Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. Mol Cell Biochem 345: 161-169, 2010.
23. Kattman SJ, Adler ED, Keller GM. Specification of multipotential cardiovascular progenitor cells during embryonic stem cell differentiation and embryonic development. Trends Cardiovasc Med 17: 240-246, 2007.
24. King KL, Winer J, Phillips DM, Quach J, Williams PM, Mather JP. Phenylephrine, endothelin, prostaglandin F2alpha' and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro. Endocrine 9: 45-55, 1998.
25. Kinugawa K, Yonekura K, Ribeiro RC, Eto Y, Aoyagi T, Baxter JD, Camacho SA, Bristow MR, Long CS, Simpson PC. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res 89: 591-598, 2001.
26. Lopaschuk GD, Jaswal JS. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol 56: 130-140, 2010.
27. Malhotra R, Brosius FC 3rd. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem 274: 12567-12575, 1999.
28. 2+ currents in rat cardiac myocytes. Membr Cell Biol 14: 109-127, 2000.
29. McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, Bisping E, Schinke M, Kong S, Sherwood MC, Brown J, Riggi L, Kang PM, Izumo S. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 279: 4782-4793, 2004.
30. Montessuit C, Rosenblatt-Velin N, Papageorgiou I, Campos L, Pellieux C, Palma T, Lerch R. Regulation of glucose transporter expression in cardiac myocytes: p38 MAPK is a strong inducer of GLUT4. Cardiovasc Res 64: 94-104, 2004.
31. Moorman AF, Lamers WH. A molecular approach towards the understanding of early heart development: an emerging synthesis. Symp Soc Exp Biol 46: 285-300, 1992.
32. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 118: 498-506, 2008.
33. Pantos C, Dritsas A, Mourouzis I, Dimopoulos A, Karatasakis G, Athanassopoulos G, Mavrogeni S, Manginas A, Cokkinos DV. Thyroid hormone is a critical determinant of myocardial performance in patients with heart failure: potential therapeutic implications. Eur J Endocrinol 157: 515-520, 2007.
34. Pantos C, Malliopoulou V, Varonos DD, Cokkinos DV. Thyroid hormone and phenotypes of cardioprotection. Basic Res Cardiol 99: 101-120, 2004.
35. Pantos C, Mourouzis I, Saranteas T, Paizis I, Xinaris C, Malliopoulou V, Cokkinos DV. Thyroid hormone receptors alpha1 and beta1 are downregulated in the post-infarcted rat heart: consequences on the response to ischaemia-reperfusion. Basic Res Cardiol 100: 422-432, 2005.
36. Pantos C, Mourouzis I, Xinaris C, Kokkinos AD, Markakis K, Dimopoulos A, Panagiotou M, Saranteas T, Kostopanagiotou G, Cokkinos DV. Time-dependent changes in the expression of thyroid hormone receptor alpha 1 in the myocardium after acute myocardial infarction: possible implications in cardiac remodelling. Eur J Endocrinol 156: 415-424, 2007.
37. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z, Cokkinos D. Thyroid hormone and "cardiac metamorphosis": potential therapeutic implications. Pharmacol Ther 118: 277-294, 2008.
38. Pantos C, Xinaris C, Mourouzis I, Perimenis P, Politi E, Spanou D, Cokkinos DV. Thyroid hormone receptor alpha 1: a switch to cardiac cell "metamorphosis"? J Physiol Pharmacol 59: 253-269, 2008.
39. Pekkanen-Mattila M, Kerkela E, Tanskanen JM, Pietila M, Pelto-Huikko M, Hyttinen J, Skottman H, Suuronen R, Aalto-Setala K. Substantial variation in the cardiac differentiation of human embryonic stem cell lines derived and propagated under the same conditions-a comparison of multiple cell lines. Ann Med 41: 360-370, 2009.
40. Pikkarainen S, Tokola H, Kerkela R, Majalahti-Palviainen T, Vuolteenaho O, Ruskoaho H. Endothelin-1-specific activation of B-type natriuretic peptide gene via p38 mitogen-activated protein kinase and nuclear ETS factors. J Biol Chem 278: 3969-3975, 2003.
41. Plomer A, Taymor KS, Scott CT. Challenges to human embryonic stem cell patents. Cell Stem Cell 2: 13-17, 2008.
42. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 12: 331-343, 2007.
43. Rao M, Condic ML. Alternative sources of pluripotent stem cells: scientific solutions to an ethical dilemma. Stem Cells Dev 17: 1-10, 2008.
44. Ray J, Noll F, Daut J, Hanley PJ. Long-chain fatty acids increase basal metabolism and depolarize mitochondria in cardiac muscle cells. Am J Physiol Heart Circ Physiol 282: H1495-H1501, 2002.
45. Raya A, Rodriguez-Piza I, Aran B, Consiglio A, Barri PN, Veiga A, Izpisua Belmonte JC. Generation of cardiomyocytes from new human embryonic stem cell lines derived from poor-quality blastocysts. Cold Spring Harb Symp Quant Biol 73: 127-135, 2008.
46. Reinecke H, Minami E, Zhu WZ, Laflamme MA. Cardiogenic differentiation and transdifferentiation of progenitor cells. Circ Res 103: 1058-1071, 2008.
47. Resnik DB. The commercialization of human stem cells: ethical and policy issues. Health Care Anal 10: 127-154, 2002.
48. Reuter H, Kokubun S, Prod'hom B. Properties and modulation of cardiac calcium channels. J Exp Biol 124: 191-201, 1986.
49. Sartipy P, Bjorquist P, Strehl R, Hyllner J. The application of human embryonic stem cell technologies to drug discovery. Drug Discov Today 12: 688-699, 2007.
50. Schaub MC, Hefti MA, Harder BA, Eppenberger HM. Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J Mol Med 75: 901-920, 1997.
51. Schenke-Layland K, Rhodes KE, Angelis E, Butylkova Y, Heydarkhan-Hagvall S, Gekas C, Zhang R, Goldhaber JI, Mikkola HK, Plath K, MacLellan WR. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells 26: 1537-1546, 2008.
52. 2+ channels. Am J Physiol Heart Circ Physiol 276: H834-H843, 1999.
53. Sheng X, Reppel M, Nguemo F, Mohammad FI, Kuzmenkin A, Hescheler J, Pfannkuche K. Human pluripotent stem cell-derived cardiomyocytes: response to TTX and lidocain reveals strong cell to cell variability. PLoS One 7: e45963, 2012.
54. Steel D, Hyllner J, Sartipy P. Cardiomyocytes derived from human embryonic stem cells-characteristics and utility for drug discovery. Curr Opin Drug Discov Devel 12: 133-140, 2009.
55. Sugden PH, Clerk A. Endothelin signalling in the cardiac myocyte and its pathophysiological relevance. Curr Vasc Pharmacol 3: 343-351, 2005.
56. Sun ZQ, Ojamaa K, Nakamura TY, Artman M, Klein I, Coetzee WA. Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes. J Mol Cell Cardiol 33: 811-824, 2001.
57. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872, 2007.
58. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006.
59. 2+-ATPase activity. Jpn J Physiol 53: 411-416, 2003.
60. Tanaka T, Tohyama S, Murata M, Nomura F, Kaneko T, Chen H, Hattori F, Egashira T, Seki T, Ohno Y, Koshimizu U, Yuasa S, Ogawa S, Yamanaka S, Yasuda K, Fukuda K. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem Biophys Res Commun 385: 497-502, 2009.
61. Vidarsson H, Hyllner J, Sartipy P. Differentiation of human embryonic stem cells to cardiomyocytes for in vitro and in vivo applications. Stem Cell Rev 6: 108-120, 2010.
62. Wei H, Juhasz O, Li J, Tarasova YS, Boheler KR. Embryonic stem cells and cardiomyocyte differentiation: phenotypic and molecular analyses. J Cell Mol Med 9: 804-817, 2005.
63. Woodcock EA, Matkovich SJ. Cardiomyocytes structure, function and associated pathologies. Int J Biochem Cell Biol 37: 1746-1751, 2005.
64. Xia Y, Buja LM, McMillin JB. Change in expression of heart carnitine palmitoyltransferase I isoforms with electrical stimulation of cultured rat neonatal cardiac myocytes. J Biol Chem 271: 12082-12087, 1996.
65. Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, Yamanaka S, Nakahata T, Heike T. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 387: 482-488, 2009.
66. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324: 797-801, 2009.
67. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920, 2007.
68. Yue DT, Herzig S, Marban E. Beta-adrenergic stimulation of calcium channels occurs by potentiation of high-activity gating modes. Proc Natl Acad Sci USA 87: 753-757, 1990.
69. Yutzey KE, Robbins J. Principles of genetic murine models for cardiac disease. Circulation 115: 792-799, 2007.
70. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104: e30-e41, 2009.
71. Zhang Y, Li TS, Lee ST, Wawrowsky KA, Cheng K, Galang G, Malliaras K, Abraham MR, Wang C, Marban E. Dedifferentiation and proliferation of mammalian cardiomyocytes. PLoS One 5: e12559, 2010.
72. Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH, Gepstein L. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation 120: 1513-1523, 2009.